Dohj LLC Has $1.09 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Dohj LLC grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.4% in the fourth quarter, HoldingsChannel reports. The fund owned 5,520 shares of the medical research company’s stock after acquiring an additional 182 shares during the period. Dohj LLC’s holdings in IQVIA were worth $1,085,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Chicago Partners Investment Group LLC boosted its holdings in IQVIA by 65.8% during the fourth quarter. Chicago Partners Investment Group LLC now owns 1,580 shares of the medical research company’s stock worth $323,000 after purchasing an additional 627 shares during the last quarter. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth about $33,000. Highland Capital Management LLC bought a new position in shares of IQVIA in the 4th quarter valued at about $1,256,000. Milestone Asset Management LLC increased its position in shares of IQVIA by 11.4% in the fourth quarter. Milestone Asset Management LLC now owns 1,998 shares of the medical research company’s stock valued at $393,000 after acquiring an additional 204 shares during the last quarter. Finally, Hanson & Doremus Investment Management raised its holdings in IQVIA by 28.7% during the fourth quarter. Hanson & Doremus Investment Management now owns 9,775 shares of the medical research company’s stock worth $1,921,000 after acquiring an additional 2,180 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on IQV. The Goldman Sachs Group lowered their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Bank of America lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Morgan Stanley cut their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Trading Down 0.2 %

Shares of IQVIA stock opened at $201.34 on Friday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The stock has a market cap of $36.54 billion, a PE ratio of 26.42, a PEG ratio of 2.12 and a beta of 1.48. The firm has a 50-day moving average of $200.41 and a 200-day moving average of $220.48. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.